Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2020, Vol. 25 ›› Issue (4): 475-480.doi: 10.12092/j.issn.1009-2501.2020.04.019

Previous Articles    

Progress in drug therapy for advanced triple-negative breast cancer

ZHAO Quanming1, YANG Yang2   

  1. 1Second Clinical Medical College of Shanxi Medical University, Taiyuan 030001, Shanxi, China;  2College of Pharmacy, Chongqing Medical University, Chongqing 400016, China
  • Received:2020-02-21 Revised:2020-03-15 Online:2020-04-26 Published:2020-05-12

Abstract: Triple-negative breast cancer is estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 negative breast cancer. The lack of specific treatment targets, there are few effective therapy for advanced triple- negative breast cancer. This article will review the current progress in drug therapy for advanced triple-negative breast cancer, including chemotherapy, targeted therapy, endocrine therapy and immunotherapy, in order to provide reference for clinical treatment.

Key words: triple-negative breast cancer, chemotherapy, targeted therapy, endocrine therapy, immunotherapy

CLC Number: